

## POSTER PRESENTATION

## Open Access

# Interleukin-6 neutralization alleviates acute exacerbation-like disease in a model of cigarette smoke-induced pulmonary inflammation

John Kubera<sup>1\*</sup>, Katherine Hammerman<sup>2</sup>, Cara MM Williams<sup>1</sup>, Cedric Hubeau<sup>1</sup>From 2nd Cross Company Respiratory Symposium  
Horsham, UK. 6-7 September 2012

Increased systemic and pulmonary levels of interleukin (IL)-6 have been associated with the severity of acute exacerbations and accelerated decline of lung function in COPD patients. The demonstration that IL-6 plays a pivotal role in AE-related pulmonary symptoms and therefore represents a therapeutic target for the treatment of COPD, remains elusive. We used a murine model where C57BL/6 female mice are exposed to cigarette smoke (CS) twice daily through a nose-only system, while being punctually challenged intranasally with poly I:C, a synthetic ligand for Toll Like Receptor-3 (TLR3). This protocol recapitulates several aspects of pulmonary inflammation as seen in acute exacerbations of COPD, including prominent airway neutrophilia as well as increased levels of type I interferon, GM-CSF, IL-6, KC, MIP-1 alpha, RANTES, and TNF-alpha in bronchoalveolar lavage (BAL) samples. Using this model, IL-6 deficient mice showed a susceptibility to CS-induced pulmonary inflammation that, overall, was comparable to that found with wild-type (WT) control mice. In contrast, using the same model with WT mice treated intraperitoneally with IL-6 neutralizing antibodies (rat IgG1, clone MP5-20F3, 25 mg/kg thrice weekly) diminished blood counts of lymphocytes ( $p=0.0070$ ) and monocytes ( $p=0.0091$ ), while this treatment also depleted BAL levels of IL-6 ( $p=0.0002$ ) and reduced BAL levels of KC ( $p=0.0220$ ). Total BAL cellularity was found to be largely decreased ( $p<0.0001$ ) as well as BAL numbers of neutrophils ( $p=0.0031$ ), lymphocytes ( $p<0.0001$ ) and macrophages ( $p<0.0001$ ), while inflammatory infiltrates seemed reduced in lung tissue sections from treated mice. Our results show that the neutralization of IL-6 largely abrogates pulmonary inflammation in CS-exposed mice, and

therefore indicate that IL-6 may be a valid therapeutic target for the treatment of COPD, in particular in episodes of acute exacerbation.

**Authors' details**

<sup>1</sup>Inflammation and Remodeling, Pfizer Cambridge, Massachusetts, 02140, USA. <sup>2</sup>Drug Safety R&D, Pfizer Cambridge, Massachusetts, 02140, USA.

Published: 14 August 2013

doi:10.1186/1476-9255-10-S1-P33

**Cite this article as:** Kubera et al.: Interleukin-6 neutralization alleviates acute exacerbation-like disease in a model of cigarette smoke-induced pulmonary inflammation. *Journal of Inflammation* 2013 **10**(Suppl 1):P33.

## Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



<sup>1</sup>Inflammation and Remodeling, Pfizer Cambridge, Massachusetts, 02140, USA  
Full list of author information is available at the end of the article